Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Content
Acute Myeloid Leukaemia
12m 22s
EHA 2022 Updates : AML
Published 11 Jul 2022
EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with addition of quizartinib to standard induction and consolidation therapy alone. Phase 3 trial results showed Decitabine as potential alternative to HSCT with similar OS but a better safety profile compared to IC (Induction Chemotherapy) in older AML pts ≥60 yrs, eligible for IC. In VIALEA and VIALEC studies AML patients treated with Venetoclax who received postremission GCSF resulted in lower duration of grade ≥3 neutropenia and febrile neutropenia.
